Public Health

For most Western governments, defending against the threat of infectious disease is now an accepted security priority. Deciding what resources and policies to put in place to protect populations from pandemics, however, involves difficult political choices. How can we get these decisions right? And what are we prepared to sacrifice to achieve better health security?

Why are rainfall, carcinogens, and primary care physicians distributed unevenly over space? The fourth edition of the leading text in the field has been updated and reorganized to cover the latest developments in disease ecology and health promotion across the globe.

This book aims to provide a collection of early ideas regarding the results of applying risk and resilience tools and strategies to COVID-19. Each chapter provides a distinct contribution to the new and rapidly growing literature on the developing COVID-19 pandemic from the vantage points of fields ranging from civil and environmental engineering to public policy, from urban planning to economics, and from public health to systems theory.

In little more than a decade the world has faced two major upheavals that few foresaw and fewer still had plans to address. As populations went into lockdown to slow the spread of COVID-19 and economic activity collapsed, many countries had barely recovered from the previous global financial crisis.The pandemic swept across Ireland in 2020 as quickly as confidence in the country's banks had vanished in 2008.

"Every year 9 million people are diagnosed with tuberculosis, every day more than 13,400 people are infected with AIDs, every 30 seconds malaria kills a child. Many people suffer and die young because they cannot access essential medicines. This book argues that people have a right to access these medicines and proposes some new Global Health Impact labelling, investment, and licensing strategies that encourage pharmaceutical companies to improve global health (global-health-impact.org/new). The idea is to rate these companies based on their medicines' impacts. Highly rated companies will get a Global Health Impact label to use on their products. Socially responsible investment companies and universities might also take the ratings into account in making investment or licensing decisions. After arguing that people do have a right to access essential medicines, this book explores this proposal, its philosophical justification, and its prospects for success"